Table 4.

Uni- and multivariate analysis by Cox-regression model for early mortality in patients with E. col BSI^a.

Variables for	Univariate analysis		Multivariate model 1			Multivariate model 2			Multivariate model 3			Multivariate model 4			Multivariate model 5			Multivariate model 6
	HR [95% CI]	P	HR [95% CI]	P	VIF	HR [95% CI]	P	VIF	HR [95% CI]	P	VIF	HR [95% CI]	P	VIF	HR [95% CI]	P	VIF	HR [95% CI]	P	VIF
Host
Critically ill	6·78 [4·75–9·69]	<0·001	5·85 [4·06–8·42]	<0·001*	1·01	5·76 [3·98–8·35]	<0·001*	1·02	5·67 [3·92–8·21]	<0·001*	1·02	5·55 [3·82–8·05]	<0·001*	1·02	5·72 [3·94–8·29]	<0·001*	1·02	5·99 [4·13–8·68]	<0·001*	1·02
Polymicrobial infection	1·72 [0·97–3·05]	0·061	1·63 [0·91–2·89]	0·098	1·01	1·57 [0·87–2·84]	0·137	1·01	1·58 [0·87–2·85]	0·130	1·01	1·49 [0·83–2·68]	0·185	1·01	1·53 [0·84–2·77]	0·164	1·01	1·53 [0·85–2·76]	0·159	1·01
Primary infection of peritoneum	4·82 [1·98–11·78]	<0·001	2·80 [1·10–7·15]	0·031	1·01	2·85 [1·13–7·18]	0·026	1·01	3·04 [1·21–7·69]	0·018	1·01	2·88 [1·12–7·42]	0·028	1·01	3·21 [1·27–8·11]	0·013	1·01	3·02 [1·20–7·63]	0·019	1·01
Primary infection of urinary tract	0·54 [0·38–0·77]	<0·001	0·56 [0·39–0·81]	<0·001*	1·03	0·55 [0·38–0·79]	0·001*	1·07	0·55 [0·38–0·79]	<0·001*	1·04	0·59 [0·41–0·85]	0·005*	1·03	0·56 [0·39–0·81]	0·002*	1·03	0·61 [0·42–0·87]	0·007*	1·03
Moderate to severe kidney disease	1·81 [1·04–3·14]	0·037				1·24 [0·69–2·22]	0·465	1·02	1·18 [0·66–2·12]	0·582	1·03	1·19 [0·66–2·15]	0·553	1·02	1·10 [0·61–1·98]	0·746	1·03	1·08 [0·59–1·96]	0·802	1·03
Chronic liver disease incl. Cirrhosis	1·80 [1·04–3·13]	0·027	2·09 [1·06–4·12]	0·033	1·00	2·11 [1·06–4·20]	0·033	1·02	1·86 [0·93–3·71]	0·080	1·02	1·97 [0·99–3·94]	0·055	1·02	1·97 [0·99–3·94]	0·053	1·02	1·84 [0·91–3·73]	0·089	1·02
White blood cells	1·01 [1·00–1·02]	0·020				1·01 [1.00–1·02]	0·148	1·01	1·01 [1·00–1·01]	0·167	1·02	1·01 [1·00–1·02]	0·072	1·01	1·00 [1·00–1·01]	0·328	1·02	1·01 [1·00–1·01]	0·157	1·02
Pathogen
Phylogenetic group B2	1·50 [1·06–2·12]	0·022				1·69 [1·18–2·42]	0·004*	1·06
ST131-sublineage H30Rx	1·89 [1·25–2·86]	0·003							2·09 [1·37–3·20]	<0·001*	1·02
MDR	1·62 [1·13–2·31]	0·008										1·59 [1·10–2·29]	0·014	1·02
Group 1 CTX-M ESBL	1·87 [1·29–2·71]	<0·001	2·05 [1·40–3·01]	<0·001*	1·02										1·94 [1·33–2·84]	<0·001*	1·02
fyuA for siderophore	1·65 [1·18–2·32]	0·004	1·53 [1·08–2·16]	0·020	1·02				1·61 [1·14–2·27]	0·007*	1·01				1·60 [1·14–2·26]	0·007*	1·01	1·59 [1·13–2·25]	0·008*	1·01
afa for invasion	1·99 [1·15–3·45]	0·015	2·21 [1·27–3·86]	0·005*	1·01	2·11 [1·19–3·73]	0·010	1·01	2·08 [1·17–3·67]	0·012	1·01				2·03 [1·14–3·60]	0·016	1·01	2·03 [1·14–3·60]	0·015	1·01
sfa/foc for adhesion	1·65 [0·98–2·77]	0·060	1·65 [0·95–2·87]	0·074	1·03							1·63 [0·95–2·79]	0·075	1·01
Treatment
Delayed definitive therapy	1·54 [0·96–2·48]	0·073																1·58 [0·97–2·55]	0·063	1·00

HR, hazard ratio; CI, confidence interval; VIF, variance inflation factor; ESBL, extended-spectrum beta-lactamase; ST, sequence type.

^aMultivariate analysis model 1 was constructed by a stepwise selection procedure and the other five from model two to model six were taken including fixed host factors, and flexible pathogen and treatment variables: phylogenetic group B2 and afa in model 2; ST131 sublineage H30Rx, fyuA and afa in model 3; MDR, and afa/foc in model 4, group 1 CTX-M ESBL production, fyuA and afa in model 5, and pathogen variables fyuA, and afa and a treatment variable. Bonferroni corrected significance level was considered as P < 0.008 and the significant P values are indicated with asterisks.